Helicobacter pylori is detected by pathogen recognition receptors including toll-like receptors (TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors, eliciting an innate immune response against this bacteria. The aim of this study was to assess if polymorphisms of TLR2, TLR4, TLR5, NOD1 and NOD2 genes are associated with gastric cancer, in particular in individuals infected with H. pylori. A case-control study of 297 gastric cancer patients and 300 controls was performed to assess the association of 17 polymorphisms. Analyses performed under the allele model did not find association with gastric cancer. However, NOD1 rs2075820 (p.E266K) showed association with intestinal-type gastric cancer among H. pylori infected subjects (OR = 2.69, 95% CI 1.41–5.13, p = 0.0026). The association was not statistically significant in diffuse-type gastric cancer cases (OR = 1.26, 95% CI 0.63–2.52, p = 0.51). When the analyses were performed in patients carrying H. pylori strains harboring the cag pathogenicity island (cagPAI), we noticed significant association with NOD1 rs2075820 (OR = 4.90, 95% CI 1.80–3.36, p = 0.0019), in particular for intestinal-type gastric cancer cases (OR = 7.16, 95% CI 2.40–21.33, p = 4.1 × 10− 4) but not among diffuse-type gastric cancer cases (OR = 3.39, 95% CI 1.13–0.10, p = 0.03). NOD1 rs2075820 increases the risk of intestinal-type gastric cancer among individuals infected with H. pylori, particularly in those harboring the cagPAI.

中文翻译：

---

NOD1 rs2075820 (p.E266K) 多态性与 cagPAI 阳性幽门螺杆菌感染个体的胃癌相关

幽门螺杆菌由病原体识别受体检测，包括 toll 样受体 (TLR) 和核苷酸结合寡聚结构域 (NOD) 样受体，引发针对这种细菌的先天免疫反应。本研究的目的是评估 TLR2、TLR4、TLR5、NOD1 和 NOD2 基因的多态性是否与胃癌相关，特别是在感染幽门螺杆菌的个体中。对 297 名胃癌患者和 300 名对照进行了病例对照研究，以评估 17 种多态性的关联。在等位基因模型下进行的分析未发现与胃癌相关。然而，NOD1 rs2075820 (p.E266K) 显示与幽门螺杆菌感染受试者的肠型胃癌相关（OR = 2.69, 95% CI 1.41–5.13, p = 0.0026）。这种关联在弥漫型胃癌病例中没有统计学意义（OR = 1.26, 95% CI 0.63–2.52, p = 0.51）。当对携带带有cag致病岛（cagPAI）的幽门螺杆菌菌株的患者进行分析时，我们注意到与NOD1 rs2075820显着相关（OR = 4.90, 95% CI 1.80–3.36, p = 0.0019），特别是对于肠道-型胃癌病例（OR = 7.16, 95% CI 2.40-21.33, p = 4.1 × 10- 4），但在弥漫型胃癌病例中不存在（OR = 3.39, 95% CI 1.13-0.10, p = 0.03）。NOD1 rs2075820 会增加感染幽门螺杆菌的个体患肠型胃癌的风险，尤其是在携带 cagPAI 的个体中。携带cag致病岛（cagPAI）的幽门螺杆菌菌株，我们注意到与NOD1 rs2075820显着相关（OR = 4.90, 95％CI 1.80-3.36，p = 0.0019），特别是对于肠型胃癌病例（OR = 7.16, 95 % CI 2.40–21.33, p = 4.1 × 10- 4) 但在弥漫型胃癌病例中不存在 (OR = 3.39, 95% CI 1.13–0.10, p = 0.03)。NOD1 rs2075820 会增加感染幽门螺杆菌的个体患肠型胃癌的风险，尤其是在携带 cagPAI 的个体中。携带cag致病岛（cagPAI）的幽门螺杆菌菌株，我们注意到与NOD1 rs2075820显着相关（OR = 4.90, 95％CI 1.80-3.36，p = 0.0019），特别是对于肠型胃癌病例（OR = 7.16, 95 % CI 2.40–21.33, p = 4.1 × 10- 4) 但在弥漫型胃癌病例中不存在 (OR = 3.39, 95% CI 1.13–0.10, p = 0.03)。NOD1 rs2075820 会增加感染幽门螺杆菌的个体患肠型胃癌的风险，尤其是在携带 cagPAI 的个体中。